ES3041762T3 - High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof - Google Patents
High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereofInfo
- Publication number
- ES3041762T3 ES3041762T3 ES21722538T ES21722538T ES3041762T3 ES 3041762 T3 ES3041762 T3 ES 3041762T3 ES 21722538 T ES21722538 T ES 21722538T ES 21722538 T ES21722538 T ES 21722538T ES 3041762 T3 ES3041762 T3 ES 3041762T3
- Authority
- ES
- Spain
- Prior art keywords
- concentration
- arginine
- ban2401
- pharmaceutical formulation
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| PCT/IB2021/000155 WO2021186245A1 (en) | 2020-03-20 | 2021-03-19 | HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3041762T3 true ES3041762T3 (en) | 2025-11-14 |
Family
ID=75746958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21722538T Active ES3041762T3 (en) | 2020-03-20 | 2021-03-19 | High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof |
Country Status (28)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021310926A1 (en) | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
| JP2024525559A (ja) | 2021-07-09 | 2024-07-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病治療用バイオマーカー |
| KR20240142535A (ko) | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
| CN120202218A (zh) | 2022-11-28 | 2025-06-24 | 卫材R&D管理有限公司 | 使用tau PET水平的治疗方法 |
| IL324807A (en) | 2023-06-09 | 2026-01-01 | Eisai R&D Man Co Ltd | Treatment methods using anti-Abeta protofibril antibody |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| MD3672631T3 (ro) | 2017-08-22 | 2023-09-30 | Biogen Ma Inc | Compoziții farmaceutice conținând anticorpi anti-beta amiloidici |
| WO2020023530A2 (en) * | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
-
2021
- 2021-03-19 PT PT217225382T patent/PT4121007T/pt unknown
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en not_active Ceased
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 PL PL21722538.2T patent/PL4121007T3/pl unknown
- 2021-03-19 HR HRP20251087TT patent/HRP20251087T1/hr unknown
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 DK DK21722538.2T patent/DK4121007T3/da active
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko active Pending
- 2021-03-19 FI FIEP21722538.2T patent/FI4121007T3/fi active
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 ES ES21722538T patent/ES3041762T3/es active Active
- 2021-03-19 MA MA59082A patent/MA59082B1/fr unknown
- 2021-03-19 SM SM20250350T patent/SMT202500350T1/it unknown
- 2021-03-19 JP JP2022556091A patent/JP7689141B2/ja active Active
- 2021-03-19 RS RS20250922A patent/RS67249B1/sr unknown
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 PH PH1/2022/552172A patent/PH12022552172A1/en unknown
- 2021-03-19 MD MDE20230104T patent/MD4121007T2/ro unknown
- 2021-03-19 SI SI202130347T patent/SI4121007T1/sl unknown
- 2021-03-19 EP EP23179487.6A patent/EP4252777B1/en active Active
- 2021-03-19 LT LTEPPCT/IB2021/000155T patent/LT4121007T/lt unknown
- 2021-03-19 IL IL326613A patent/IL326613A/en unknown
- 2021-03-19 EP EP21722538.2A patent/EP4121007B1/en active Active
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-19 HU HUE21722538A patent/HUE072937T2/hu unknown
- 2021-03-22 TW TW110110263A patent/TWI923576B/zh active
-
2022
- 2022-08-04 IL IL295383A patent/IL295383B2/en unknown
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
-
2024
- 2024-11-08 CL CL2024003428A patent/CL2024003428A1/es unknown
-
2025
- 2025-04-10 JP JP2025064827A patent/JP2025111516A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI923576B (zh) | 高濃度抗Aβ原纖維抗體配製物及其使用方法 | |
| ES2947488T3 (es) | Formulación anti-IFNAR1 estable | |
| JP5513380B2 (ja) | 肝細胞増殖因子に対する特異的結合剤の組成物 | |
| TWI764097B (zh) | 包含抗cd47抗體的製劑及其製備方法和用途 | |
| BR112012012080B1 (pt) | Formulações de histidina-trealose do anticorpo t1h | |
| CN104159612B (zh) | Il-17抗体制剂 | |
| KR20160068946A (ko) | 안정한 수성 항체 제제 | |
| BR112021007946A2 (pt) | formulação de anticorpo | |
| US12358981B2 (en) | Anti-connexin antibody formulations | |
| WO2017104778A1 (ja) | 抗ヒトtslp受容体抗体含有医薬組成物 | |
| CN115803011A (zh) | 用于高度浓缩蛋白质制剂的粘度降低赋形剂及其组合 | |
| CN114423414A (zh) | 樟脑磺酸及其与阳离子赋形剂的组合作为高浓缩蛋白质制剂中的降粘剂 | |
| US20200299371A1 (en) | Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody | |
| RU2846725C1 (ru) | ВЫСОКОКОНЦЕНТРИРОВАННЫЕ СОСТАВЫ НА ОСНОВЕ АНТИТЕЛ К ПРОТОФИБРИЛЛАМ Аβ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| BR122025027938A2 (pt) | FORMULAÇÕES DE ANTICORPO DE PROTOFIBRILA ANTI-Abeta DE CONCENTRAÇÃO ALTA E MÉTODOS DE USO DAS MESMAS | |
| HK40102754A (en) | High concentration anti-ass protofibril antibody formulations and methods of use thereof | |
| HK40085437B (en) | High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof | |
| HK40085437A (en) | High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof | |
| KR20240038005A (ko) | B7-h3 항체의 약학적 조성물 및 그것의 용도 | |
| HK40059591A (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor | |
| BR112018010211B1 (pt) | Formulação farmacêutica aquosa de anticorpo, seu uso e frasco compreendendo a mesma | |
| BR112020004902B1 (pt) | Processo para formulação farmacêutica liofilizada de uma proteína terapêutica | |
| HK1257781A1 (zh) | 含抗-pd-l1抗体avelumab的水性药物制剂 | |
| BR112019007858B1 (pt) | Composições farmacêuticas, métodos relacionados, kit, recipiente de dose única e uso |